Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 846,885
  • Shares Outstanding, K 106,126
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,190 K
  • EBIT $ -304 M
  • EBITDA $ -309 M
  • 60-Month Beta 1.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.08

Options Overview Details

View History
  • Implied Volatility 67.24% ( +12.61%)
  • Historical Volatility 80.76%
  • IV Percentile 16%
  • IV Rank 34.44%
  • IV High 141.91% on 10/01/24
  • IV Low 28.02% on 08/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 105
  • Volume Avg (30-Day) 1,194
  • Put/Call OI Ratio 1.58
  • Today's Open Interest 18,178
  • Open Int (30-Day) 20,120

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 5
  • High Estimate -0.56
  • Low Estimate -1.03
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -58.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.67 +9.26%
on 11/01/24
10.72 -21.83%
on 11/11/24
+0.25 (+3.08%)
since 10/21/24
3-Month
7.00 +19.71%
on 10/03/24
10.72 -21.83%
on 11/11/24
-0.52 (-5.84%)
since 08/21/24
52-Week
7.00 +19.71%
on 10/03/24
16.63 -49.61%
on 03/04/24
+0.79 (+10.41%)
since 11/21/23

Most Recent Stories

More News
89bio, Inc. Presents New Data from Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024

89bio presented new Phase 2b trial data on pegozafermin for treating advanced MASH, highlighting potential benefits in fibrosis reversal.Quiver AI Summary89bio, Inc. announced new analyses from its Phase...

ETNB : 8.38 (+5.01%)
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

ETNB : 8.38 (+5.01%)
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB : 8.38 (+5.01%)
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

ETNB : 8.38 (+5.01%)
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

ETNB : 8.38 (+5.01%)
89bio to Participate in the UBS Global Healthcare Conference

ETNB : 8.38 (+5.01%)
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

ETNB : 8.38 (+5.01%)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB : 8.38 (+5.01%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 2.72 (-3.37%)
GLMD : 2.80 (-5.41%)
VKTX : 51.63 (+0.19%)
ETNB : 8.38 (+5.01%)
IVA : 2.66 (-2.92%)
SGMT : 4.50 (-0.44%)
TERN : 5.71 (+1.96%)
NVO : 102.63 (-2.51%)
IQV : 197.60 (+1.66%)
MDGL : 329.24 (+3.83%)
Why Shares of 89bio Plummeted on Tuesday

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

AKRO : 31.20 (+1.84%)
ETNB : 8.38 (+5.01%)

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 9.47
2nd Resistance Point 9.02
1st Resistance Point 8.70
Last Price 8.38
1st Support Level 7.93
2nd Support Level 7.48
3rd Support Level 7.16

See More

52-Week High 16.63
Fibonacci 61.8% 12.95
Fibonacci 50% 11.81
Fibonacci 38.2% 10.68
Last Price 8.38
52-Week Low 7.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar